Aspen is a global supplier of branded and generic pharmaceutical products as well as infant nutritionals and consumer healthcare products in selected territories.

Financial highlights

Value Aspen has

Aspen recognises the importance of creating value for all its stakeholders.

This diagram indicates how Aspen’s wealth has been distributed and reinvested.

Who we are

Why invest in Aspen?

Aspen has a proud heritage dating back more than 160 years and is committed to sustaining life and promoting healthcare through increasing access to its high quality, affordable medicines and products.

Click on numbers below for more information

  • 1Strong market position
    • One of the largest pharmaceutical companies in the southern hemisphere
    • Substantial presence in major developing markets such as Latin America, Russia, Eastern Europe, sub-Saharan Africa (“SSA”) and South East Asia
    • Accredited manufacturing facilities that are scalable to demand
    • Vertical integration advantages for the manufacture of certain of Aspen’s leading global brands
    • The leading pharmaceutical company in South Africa
    • One of the top five pharmaceutical companies in Australia
  • 2Diversified geographies and product offering
    • Well positioned in both developing and developed territories with products distributed to more than 150 countries
    • More than 75% of revenues and EBITA are generated from territories outside of South Africa
    • A broad product portfolio including branded medicines, biologicals, generics, infant nutritionals and other consumer healthcare products
    • Diverse manufacturing capabilities across 26 manufacturing facilities covering a wide variety of product-types including oral solid dose, liquids, semi-solids, steriles, biologicals, active pharmaceuticals ingredients (“API”) and nutritionals
    • Diversification of geopolitical and currency risk
  • 3Proven track record
    • Delivered double-digit earnings growth to its shareholders for 17 consecutive years
    • Total shareholder return of 17 712% from listing until 30 June 2015 equating to a 36% CAGR
    • Five-year shareholder return to 30 June 2015 of 40% equating to a CAGR of 38%
    • CAGR since listing in excess of 40% for revenue, operating profit and NHEPS
    • Skilled and experienced management team to execute Aspen’s strategy across multiple territories
  • 4Leverages on local knowledge and expertise
    • Empowered local management take ownership of their businesses and are responsible for growth in their respective markets
    • Products are acquired and product pipeline is developed in line with targeted therapeutic categories for each region
  • 5Centralised Group activities facilitate synergies and mitigate pricing pressures
    • Globally competitive manufacturing facilities that are aligned to commercial objectives and provide economies of scale
    • Centralised regulatory, supply chain and procurement resources provide competitive advantages for the Group
    • An ongoing focus on continuous improvement of efficiencies and performance
  • 6Positive growth drivers
    • Provider of high quality, affordable, medicines and products to historically under-served markets
    • Exposure to faster growing developing markets
    • Expanding footprint in targeted strategic growth territories
    • Ongoing consolidation of production volumes and procurement efficiencies at strategic manufacturing sites will deliver competitive advantages to the Group
    • Capital investment in production technologies and capacities to harness synergies from recent acquisitions in the medium term
    • Strong cash generation enables reinvestment into the business
  • 7Responsible corporate citizen
    • Committed to pursuing the Group’s strategic objectives in a responsible and sustainable manner
    • Operates on an established foundation of strong corporate governance
    • Participant in the United Nations Global Compact (“UN Global compact”) initiative
    • Has qualified for the JSE Socially Responsible Investment (“SRI”) index each year since first applying for participation in 2010
    • Participant in the annual Carbon Disclosure and Water Disclosure Projects
    • Focused investment for the development of our human capital and empowerment of future leaders
  • 8Other considerations
    • Aspen has good trading liquidity with an average daily trading volume of more than one million shares
    • Aspen’s executive directors are founders and material shareholders of the Group, ensuring alignment of shareholders’ and executives’ interests
    • The defensive nature of the pharmaceutical industry makes it less vulnerable to economic fluctuations
Designed and produced by: Element